In a lecture at VMX, Jason B. Pieper, DVM, MS, DACVD, outlined the next steps in the treatment of pyoderma in dogs when the ...

Among children treated with an oral agent, the recurrence rate was 16/42 (38.1%) following penicillin or amoxicillin and 10/36 (27.8%) following a beta-lactamase resistant agent (adjusted odds ...

This rate is higher than observed in children treated with a beta-lactamase resistant agent, although the associated risk estimate reached statistical significance (pooled OR: 2.39 [95% CI ...

This study reports a high prevalence of ESBL-PE associated with strong resistance to quinolones and cotrimoxazole (over 80%), which calls for increased surveillance of these superbugs, the adoption of ...

This study reports a high prevalence of ESBL-PE associated with strong resistance to quinolones and cotrimoxazole (over 80%), which calls for increased surveillance of these superbugs, the adoption of ...

beta-lactamase-resistant penicillins, glycopeptides, and fluoroquinolones. The drugs with a compound annual growth rate that increased by more than 20% from 2018 to 2021 were amikacin (50.12%), ...

Beta-lactamase inhibitors are designed to overcome a key resistance mechanism that allows pathogens to protect themselves from beta-lactams, one of the most commonly-used antibiotic classes.

Its ORAvance, an oral treatment beta-lactamase inhibitor targeting extended-spectrum beta-lactamase (ESBL) and carbapenem-resistant Enterobacteriaceae (CRE) infections; OMNIvance drug against ...